Wide Ranks

NAMSW

NewAmsterdam Pharma Company N.V

9.69

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 889.80 %
Current Ratio 10.61 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins -85.89 %
Balance Sheet
Total Cash 422 M Total Cash Per Share 4.58 Total Debt 506000
Total Debt To Equity 0.1340 Current Ratio 10.61 Book Value Per Share 4.11
All Measures
Message Board Id finmb_685404834 Return On Equity -0.4737 City Naarden
Uuid 072ede56-783e-317d-b7d9-5dc797a27eef Previous Close 9.55 First Trade Date Epoch Utc 1 B
Book Value 4.11 Beta -0.0010 Total Debt 506000
Volume 10020 Price To Book 2.36 Fifty Two Week Low 1.81
Total Cash Per Share 4.58 Total Revenue 33 M Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -85.89 % Net Income To Common -198916000
Trailing Peg Ratio None Average Daily Volume10 Day 13160 Average Volume10days 13160
Total Cash 422 M Revenue Per Share 0.3730 Trailing PE 0.0000
Regular Market Previous Close 9.55 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 9.30 Open 10.03 Free Cashflow -108734752
Dividend Yield 0.00 % Return On Assets -0.2927 Time Zone Short Name EST
Day Low 9.50 Address1 Gooimeer 2-35 Target High Price 0.0000
Price Hint 2 Website https://www.newamsterdampharma.com 52 Week Change 3.14
Average Volume 5729 Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 1037.10 % Is_sp_500 False
Regular Market Day High 10.03 Profit Margins 0.00 % Debt To Equity 0.1340
Fifty Two Week High 16.75 Day High 10.03 Regular Market Open 10.03
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 889.80 %
Operating Cashflow -154156992 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Market Cap 0.0000 Zip 1411 DC
Quote Type EQUITY Industry Biotechnology Long Name NewAmsterdam Pharma Company N.V.
Regular Market Day Low 9.50 Current Price 9.69 Financial Currency USD
Current Ratio 10.61 Gross Margins 100.00 % Industry Disp Biotechnology
Country Netherlands Float Shares 36 M Two Hundred Day Average 9.12
Forward PE 0.0000 Regular Market Volume 10020 Ebitda -184059008
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
NewAmsterdam Pharma Company N.

V.

, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.

It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.

NewAmsterdam Pharma Company N.

V.

is headquartered in Naarden, the Netherlands.